Skip to main
MRNA

Moderna (MRNA) Stock Forecast & Price Target

Moderna (MRNA) Analyst Ratings

Based on 12 analyst ratings
Hold
Strong Buy 0%
Buy 8%
Hold 67%
Sell 25%
Strong Sell 0%

Bulls say

Moderna is a commercial-stage biotech that specializes in developing transformative medicines based on mRNA technology. With 35 mRNA development candidates in clinical studies, the firm has a wide range of potential treatments in its pipeline, including for infectious diseases, oncology, cardiovascular disease, and rare genetic diseases. The company's success with its COVID-19 vaccine has led to significant revenue and opportunities for growth, such as in the flu and RSV markets. In addition to its strong current product offerings, Moderna also has promising early-stage programs for rare diseases and potential for its cancer vaccine to become the next PD-1. However, there are risks to consider, such as potential clinical failures and pricing pressure in the market, which may impact the company's financial performance.

Bears say

Moderna is a commercial-stage biotech with a negative outlook due to potential competition, regulatory uncertainties, and long-term pricing pressure in the space. While the company has shown progress and has a diversified pipeline, its recent IP settlement and market cap of $18 billion may present a balanced risk/reward ratio for investors. With many promising programs in various stages of development, Moderna will continue to face competition in the rapidly evolving biotech industry.

Moderna (MRNA) has been analyzed by 12 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 8% recommend Buy, 67% suggest Holding, 25% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Moderna and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Moderna (MRNA) Forecast

Analysts have given Moderna (MRNA) a Hold based on their latest research and market trends.

According to 12 analysts, Moderna (MRNA) has a Hold consensus rating as of May 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $37.42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $37.42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Moderna (MRNA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.